Sfoglia per Autore
Tipranavir (TPV) genotypic Inhibitory Quotient (gIQ) predicts virological responce at 24 weeks to TPV-based salvage regimens.
2006-01-01 Bonora S; Gonzalez de Requena D; Calcagno A; Milia MG; D’Avolio A; Sciandra M; Garazzino S; Siccardi M; Sinicco A; Di Perri G.
Unexpected drug-drug interaction between tipranavir/ritonavir (TPV/RTV) and enfuvirtide (T20)
2006-01-01 Gonzalez de Requena D; Calcagno A; Bonora S; Ladetto L; D’Avolio A; Sciandra M; Siccardi M; Bargiacchi O; Sinicco A; Di Perri G.
A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method
2007-01-01 D'AVOLIO A; SCIANDRA M; SICCARDI M; BAIETTO L; DE REQUENA DG; BONORA S; DI PERRI G
HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients
2007-01-01 A. D'AVOLIO; M. SICCARDI; M. SCIANDRA; L. BAIETTO; S. BONORA; L. TRENTINI; G. DI PERRI
PXR 63396C>T is a predictor of boosted and unboosted atazanavir plasma concentrations
2008-01-01 Siccardi M; D'Avolio A; Baietto L; Bonora S; Gatti D; Calcagno A; Oddone V; Simiele M; Sciandra M; Khoo S; Back D; Owen A; Di Perri G.
Plasma concentration of boosted and unboosted Atazanavir are predicted by 63396C>T SNP in the PXR gene
2008-01-01 Siccardi M; D'Avolio A; Baietto L; Calcagno A; Gibbons S; Sciandra M; Bonora S; Khoo S; Back D; Di Perri G; Owen A
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients.
2008-01-01 Bonora S; D'Avolio A; Tettoni C; Siccardi M; Gonzalez de Requena D; Baietto L; Cometto C; Sciandra M; Trentini L; Di Perri G.
Le concentrazioni plasmatriche di ATV boostato ed unboosted correlano con il polimorfismo 63396C>T del pregnane X receptor.
2008-01-01 M. Siccardi; A. D'Avolio; L. Baietto; D. Gatti; A. Calcagno; S. Gibbons; M. Sciandra; S. Bonora; S. Khoo; D. Back; G. Di Perri; A. Owen.
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir
2008-01-01 Marco Siccardi; Antonio D'Avolio; Lorena Baietto; Sara Gibbons; Mauro Sciandra; Daniela Colucci; Stefano Bonora; Saye Khoo; David J Back; Giovanni Di Perri; Andrew Owen
An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients
2008-01-01 Antonio Dʼavolio; Lorena Baietto; Marco Siccardi; Mauro Sciandra; Marco Simiele; Valentina Oddone; Stefano Bonora; Giovanni Di Perri
A Simple and Fast Method for Quantification of Ertapenem using Meropenem as Internal Standard in Human Plasma in a Clinical Setting
2008-01-01 D'AVOLIO A; BAIETTO L; DE ROSA FG; GARAZZINO S; SCIANDRA M; SICCARDI M; BONORA S; DI PERRI G
A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients
2008-01-01 Antonio D'Avolio; Mauro Sciandra; Marco Siccardi; Lorena Baietto; Daniel Gonzalez de; Stefano Bonora; Giovanni Di Perri
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens
2008-01-01 Daniel Gonzalez de; Stefano Bonora; Andrea Calcagno; Antonio D'Avolio; Marco Siccardi; Silvia Fontana; Maria Grazia Milia; Mauro Sciandra; Silvia Garazzino; Antonio Di Garbo; Lorena Baietto; Laura Trentini; Giovanni Di Perri
Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia
2008-01-01 Garazzino S; Aprato A; Baietto L; D'Avolio A; Maiello A; De Rosa FG; Aloj D; Siccardi M; Biasibetti A; Massè A; Di Perri G.
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon
2008-01-01 MARUCCO DA; DE REQUENA DG; BONORA S; TETTONI C; BONASSO M; DE BLASI T; D'AVOLIO A; SCIANDRA M; SICCARDI M; BAIETTO L; TRENTINI L; SINICCO A; CARITI G; DI PERRI G
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance
2009-01-01 Schipani A; Siccardi M; D'Avolio A; Baietto L; Calcagno A; Tettoni C; Bonora S; Davis G; Khoo S; Back DJ; Di Perri G; Owen A
Evaluation of 7 different resistence interpretation algoritms and their derived gentotypic inhibitory quotients for the prediction of 48-week virological response to darunavir-based salvage regimens
2009-01-01 D. Gonzalez de Requena; S. Bonora; A. Calcagno; A. D’Avolio; O. Viganò; L. Baietto; C. Cometto; V. Ghisetti; M. Siccardi; S. Rusconi; G. Di Perri
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks
2009-01-01 Gonzalez de Requena D; Bonora S; Cometto C; Magnani S; D'Avolio A; Milia M; Vigano' O; Di Garbo A; Calcagno A; Siccardi M; Baietto L; Sciandra M; Rusconi S; Di Perri G.
Farmacocinetica della caspofungina in pazienti sottoposti a trapianto epatico.
2009-01-01 Baietto L; D'Avolio A; De Rosa FG; Garazzino S; Siccardi M; Simiele M; Sciandra M; Salizzoni M; Di Perri G
Influenza dei polimorfismi C3453T, C1236T, G2677T/A del gene MDR1 sulle concentrazioni plasmatiche di daptomicina
2009-01-01 Baietto L; D'Avolio A; De Rosa FG; Michelazzo M; Garazzino S; Vizio L; Simiele M; Siccardi M; Di Perri G
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Tipranavir (TPV) genotypic Inhibitory Quotient (gIQ) predicts virological responce at 24 weeks to TPV-based salvage regimens. | 2006 | Bonora S; Gonzalez de Requena D; Calcagno A; Milia MG; D’Avolio A; Sciandra M; Garazzino S; Siccardi M; Sinicco A; Di Perri G. | |
| Unexpected drug-drug interaction between tipranavir/ritonavir (TPV/RTV) and enfuvirtide (T20) | 2006 | Gonzalez de Requena D; Calcagno A; Bonora S; Ladetto L; D’Avolio A; Sciandra M; Siccardi M; Bargiacchi O; Sinicco A; Di Perri G. | |
| A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method | 2007 | D'AVOLIO A; SCIANDRA M; SICCARDI M; BAIETTO L; DE REQUENA DG; BONORA S; DI PERRI G | |
| HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients | 2007 | A. D'AVOLIO; M. SICCARDI; M. SCIANDRA; L. BAIETTO; S. BONORA; L. TRENTINI; G. DI PERRI | |
| PXR 63396C>T is a predictor of boosted and unboosted atazanavir plasma concentrations | 2008 | Siccardi M; D'Avolio A; Baietto L; Bonora S; Gatti D; Calcagno A; Oddone V; Simiele M; Sciandra M; Khoo S; Back D; Owen A; Di Perri G. | |
| Plasma concentration of boosted and unboosted Atazanavir are predicted by 63396C>T SNP in the PXR gene | 2008 | Siccardi M; D'Avolio A; Baietto L; Calcagno A; Gibbons S; Sciandra M; Bonora S; Khoo S; Back D; Di Perri G; Owen A | |
| A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients. | 2008 | Bonora S; D'Avolio A; Tettoni C; Siccardi M; Gonzalez de Requena D; Baietto L; Cometto C; Sciandra M; Trentini L; Di Perri G. | |
| Le concentrazioni plasmatriche di ATV boostato ed unboosted correlano con il polimorfismo 63396C>T del pregnane X receptor. | 2008 | M. Siccardi; A. D'Avolio; L. Baietto; D. Gatti; A. Calcagno; S. Gibbons; M. Sciandra; S. Bonora; S. Khoo; D. Back; G. Di Perri; A. Owen. | |
| Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir | 2008 | Marco Siccardi; Antonio D'Avolio; Lorena Baietto; Sara Gibbons; Mauro Sciandra; Daniela Colucci; Stefano Bonora; Saye Khoo; David J Back; Giovanni Di Perri; Andrew Owen | |
| An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients | 2008 | Antonio Dʼavolio; Lorena Baietto; Marco Siccardi; Mauro Sciandra; Marco Simiele; Valentina Oddone; Stefano Bonora; Giovanni Di Perri | |
| A Simple and Fast Method for Quantification of Ertapenem using Meropenem as Internal Standard in Human Plasma in a Clinical Setting | 2008 | D'AVOLIO A; BAIETTO L; DE ROSA FG; GARAZZINO S; SCIANDRA M; SICCARDI M; BONORA S; DI PERRI G | |
| A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients | 2008 | Antonio D'Avolio; Mauro Sciandra; Marco Siccardi; Lorena Baietto; Daniel Gonzalez de; Stefano Bonora; Giovanni Di Perri | |
| Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens | 2008 | Daniel Gonzalez de; Stefano Bonora; Andrea Calcagno; Antonio D'Avolio; Marco Siccardi; Silvia Fontana; Maria Grazia Milia; Mauro Sciandra; Silvia Garazzino; Antonio Di Garbo; Lorena Baietto; Laura Trentini; Giovanni Di Perri | |
| Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia | 2008 | Garazzino S; Aprato A; Baietto L; D'Avolio A; Maiello A; De Rosa FG; Aloj D; Siccardi M; Biasibetti A; Massè A; Di Perri G. | |
| The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon | 2008 | MARUCCO DA; DE REQUENA DG; BONORA S; TETTONI C; BONASSO M; DE BLASI T; D'AVOLIO A; SCIANDRA M; SICCARDI M; BAIETTO L; TRENTINI L; SINICCO A; CARITI G; DI PERRI G | |
| A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance | 2009 | Schipani A; Siccardi M; D'Avolio A; Baietto L; Calcagno A; Tettoni C; Bonora S; Davis G; Khoo S; Back DJ; Di Perri G; Owen A | |
| Evaluation of 7 different resistence interpretation algoritms and their derived gentotypic inhibitory quotients for the prediction of 48-week virological response to darunavir-based salvage regimens | 2009 | D. Gonzalez de Requena; S. Bonora; A. Calcagno; A. D’Avolio; O. Viganò; L. Baietto; C. Cometto; V. Ghisetti; M. Siccardi; S. Rusconi; G. Di Perri | |
| Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks | 2009 | Gonzalez de Requena D; Bonora S; Cometto C; Magnani S; D'Avolio A; Milia M; Vigano' O; Di Garbo A; Calcagno A; Siccardi M; Baietto L; Sciandra M; Rusconi S; Di Perri G. | |
| Farmacocinetica della caspofungina in pazienti sottoposti a trapianto epatico. | 2009 | Baietto L; D'Avolio A; De Rosa FG; Garazzino S; Siccardi M; Simiele M; Sciandra M; Salizzoni M; Di Perri G | |
| Influenza dei polimorfismi C3453T, C1236T, G2677T/A del gene MDR1 sulle concentrazioni plasmatiche di daptomicina | 2009 | Baietto L; D'Avolio A; De Rosa FG; Michelazzo M; Garazzino S; Vizio L; Simiele M; Siccardi M; Di Perri G |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile